The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the CenturyInvestorPlace • 07/01/21
Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC EndorsementGlobeNewsWire • 06/23/21
Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory OfficerGlobeNewsWire • 06/15/21
Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term GrowthGlobeNewsWire • 06/14/21
Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association CongressGlobeNewsWire • 06/11/21
Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Domino's, Editas, Roblox, Teva, US Steel and More Tuesday Afternoon Analyst Calls24/7 Wall Street • 05/04/21
Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 05/04/21
Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual MeetingGlobeNewsWire • 05/01/21